OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 03:37:00 2024-05-28 pm EDT | ||
| 3.2 EUR | +0.63% |
|
| Current month | -8.57% | ||
| 1 month | -13.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 3.2 | +0.63% |
| 24-05-27 | 3.18 | +4.61% |
| 24-05-24 | 3.04 | -0.33% |
| 24-05-23 | 3.05 | -4.39% |
| 24-05-22 | 3.19 | +0.63% |
Delayed Quote Deutsche Boerse AG
Last update May 28, 2024 at 03:37 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU01F8 |
| ISIN | DE000SU01F81 |
| Date issued | 2023-10-23 |
| Strike | 1,162 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.51 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.95 € |
|---|---|
| Lowest since issue | 2.91 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
